Nausea, diarrhea, vomiting, constipation, abdominal discomfort, indigestion, bloating, and reflux appear prominently in current prescribing information for semaglutide and tirzepatide
Compounding can serve an important role when a patient has a real medical need
AOD 9604 works by stimulating fat cell receptor pathways, not by enhancing exercise performance
Instead of working through a single pathway, it helps regulate hunger, blood sugar, and fat metabolism simultaneously, making it one of the most advanced tools currently available in metabolic medicine
The evidence for this is weak at best
Tirzepatide reconstitution by vial size (units assume U-100 insulin syringes) Vial 5 mg BAC water 1.0 mL Concentration 5 mg/mL 2.5 mg 0.50 mL / 50 u 5 mg 1.00 mL / 100 u 7.5 mg 10 mg 15 mg Vial 10 mg BAC water 1.0 mL Concentration 10 mg/mL 2.5 mg 0.25 mL / 25 u 5 mg 0.50 mL / 50 u 7.5 mg 0.75 mL / 75 u 10 mg 1.00 mL / 100 u 15 mg Vial 10 mg BAC water 2.0 mL Concentration 5 mg/mL 2.5 mg 0.50 mL / 50 u 5 mg 1.00 mL / 100 u 7.5 mg 10 mg 15 mg Vial 15 mg BAC water 1.5 mL Concentration 10 mg/mL 2.5 mg 0.25 mL / 25 u 5 mg 0.50 mL / 50 u 7.5 mg 0.75 mL / 75 u 10 mg 1.00 mL / 100 u 15 mg 1.50 mL / split Vial 40 mg BAC water 2.0 mL Concentration 20 mg/mL 2.5 mg 0.125 mL / 12.5 u 5 mg 0.25 mL / 25 u 7.5 mg 0.375 mL / 37.5 u 10 mg 0.50 mL / 50 u 15 mg 0.75 mL / 75 u Vial 40 mg BAC water 3.0 mL Concentration 13.33 mg/mL 2.5 mg 0.188 mL / 18.8 u 5 mg 0.375 mL / 37.5 u 7.5 mg 0.563 mL / 56.3 u 10 mg 0.75 mL / 75 u 15 mg 1.125 mL / split Vial 60 mg BAC water 3.0 mL Concentration 20 mg/mL 2.5 mg 0.125 mL / 12.5 u 5 mg 0.25 mL / 25 u 7.5 mg 0.375 mL / 37.5 u 10 mg 0.50 mL / 50 u 15 mg 0.75 mL / 75 u 20 mg/mL keeps 40 mg and 60 mg vial setups within a 3 mL vial-capacity ceiling while keeping the listed doses compact
